• Alias: MGCD0103
    • Benzamide HDAC inhibitor
    • Previous clinical trials for leukemia and lymphoma showed promising activity; currently in phase 1 clinical trial for MDS
    • Recommended phase 2 dose: 45 mg PO, t.i.w.
    • Half-life: 6.7 to 12.2 hours
    • Common side effects: Fatigue, nausea/vomiting, anorexia, dehydration
    (Siu et al., 2008)
    Other topics in Targeted and Immunotherapy Agents